99mTc-CNDG SPECT/CT in Brain Tumors

Chinese Academy of Medical Sciences & Peking Union Medical College

Status

Enrolling

Conditions

Intracranial Tumor

Treatments

Diagnostic Test: 99mTc-CNDG SPECT/CT

Study type

Interventional

Funder types

Other

Identifiers

NCT06362304

2024-DG-01

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:

What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?
What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?

Participants will:

Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with clinical diagnosis of brain tumor;
Be at least 18 years old;
The final pathological results could be obtained by surgery or biopsy;
Informed consent and the ability to be followed up;
Those who did not meet the exclusion criteria.

Exclusion criteria

Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before 99mTc-CNDG injection;
Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
Severe hypersensitivity or hypersensitivity to radiocontrast agents;
Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
Patients receiving radiotherapy and chemotherapy;
Being pregnant or breastfeeding.